Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review

(2016) Alan Hoi Lun Yau et al.   Canadian Journal of Gastroenterology and Hepatology

Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs

(2015) Donald W. Light et al.   JOURNAL OF LAW MEDICINE & ETHICS

Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health

(2015) Marc-André Gagnon   JOURNAL OF LAW MEDICINE & ETHICS

Institutional Corruption and the Pharmaceutical Policy

(2015) Marc A. Rodwin   JOURNAL OF LAW MEDICINE & ETHICS

Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation

(2014) Anne-Sophie Larock et al.   ANNALS OF PHARMACOTHERAPY

Ado-trastuzumab Emtansine

(2014) Patricia A. Corrigan et al.   ANNALS OF PHARMACOTHERAPY

Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England

(2014) Sarah J. Mansfield   Australian Health Review

An Analytical Framework for Assessing Drug and Therapeutics Committee Structure and Work Processes in Tertiary Brazilian Hospitals

(2014) Elisangela da Costa Lima-Dellamora et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

(2014) Brian Godman et al.   BMC Medicine

Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004–2011

(2014) Jing Luo et al.   BMC PUBLIC HEALTH

Interventions promoting the acceptance and uptake of generic medicines: A narrative review of the literature

(2014) Z.U.D. Babar et al.   HEALTH POLICY

Systematic review of factors affecting pharmaceutical expenditures

(2014) Mohamed Awad Mousnad et al.   HEALTH POLICY

Treatment of Hepatitis C

(2014) Anita Kohli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

New Expensive Treatments for Hepatitis C Infection

(2014) Troyen Brennan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care

(2014) Ronan J Kelly et al.   LANCET ONCOLOGY

Shining a light in the black box of orphan drug pricing

(2014) Eline Picavet et al.   Orphanet Journal of Rare Diseases

Comment on “Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary”

(2014) Scott Metcalfe et al.   PHARMACOECONOMICS

Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary

(2014) Robin Gauld   PHARMACOECONOMICS

Identifying priority medicines policy issues for New Zealand: a general inductive study

(2014) Zaheer-Ud-Din Babar et al.   BMJ Open

Dabigatran: how the drug company withheld important analyses

(2014) D. Cohen   BMJ-British Medical Journal

Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding

(2014) D. Cohen et al.   BMJ-British Medical Journal

NICE says drug for metastatic breast cancer is unaffordable for NHS

(2014) Z. Kmietowicz   BMJ-British Medical Journal

What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?

(2014) Michael Wonder   Expert Review of Pharmacoeconomics & Outcomes Research

Sofosbuvir (Sovaldi) for the treatment of hepatitis C

(2014) Brian Lam et al.   Expert Review of Clinical Pharmacology

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications

(2014) James C. Moon et al.   Frontiers in Pharmacology

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Personalizing health care: feasibility and future implications

(2013) Brian Godman et al.   BMC Medicine

Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations

(2013) Linda Björkhem-Bergman et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France

(2013) P. B. Van Wilder et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs

(2013) Amelia Troncoso et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study

(2013) R. Joppi et al.   European Journal of Internal Medicine

Pricing for Orphan Drugs

(2013) Brian P. O’Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cancer Drugs in the United States: Justum Pretium—The Just Price

(2013) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

(2013) Steven E Kahn et al.   LANCET

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

(2013) Thomas Morel et al.   Orphanet Journal of Rare Diseases

Early Scientific Advice Obtained Simultaneously from Regulators and Payers: Findings from a Pilot Study in Australia

(2013) Michael Wonder et al.   VALUE IN HEALTH

Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model

(2013) David M Brogan et al.   Globalization and Health

Is there a cure for corporate crime in the drug industry?

(2013) C. Davis et al.   BMJ-British Medical Journal

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

(2013) P. Raaschou et al.   BMJ-British Medical Journal

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

(2013) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Understanding the Role and Evidence Expectations of Health Technology Assessment and Coverage/Payer Bodies

(2013) Chris Henshall et al.   Therapeutic Innovation & Regulatory Science

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

(2013) Rickard E. Malmström et al.   Frontiers in Pharmacology

Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009

(2013) Frank R. Lichtenberg   Health Policy and Technology

Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden

(2013) Brian Godman et al.   Applied Health Economics and Health Policy

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

(2013) Brian Godman et al.   Applied Health Economics and Health Policy

Pharmaceutical Companies’ Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination

(2012) Michelle M. Mello et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Forecasting drug utilization and expenditure in a metropolitan health region

(2012) Björn Wettermark et al.   BMC HEALTH SERVICES RESEARCH

Placebo? no thanks, it might be bad for me!

(2012) Silvio Garattini et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU

(2012) Roberta Joppi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Stakeholder involvement in expensive drug recommendation decisions: An international perspective

(2012) Zahava R.S. Rosenberg-Yunger et al.   HEALTH POLICY

Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000–2010

(2012) Warren A. Kaplan et al.   HEALTH POLICY

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 – a retrospective analysis

(2012) Valerie Nell-Duxneuner et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

ANALYZING 10 YEARS OF EARLY AWARENESS AND ALERT ACTIVITY IN THE UNITED KINGDOM

(2012) Claire Packer et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy

(2012) E. Braunlin et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Longterm Retention of Tumor Necrosis Factor-  Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

(2012) F. IANNONE et al.   JOURNAL OF RHEUMATOLOGY

Over 150 potentially low-value health care practices: an Australian study

(2012) Adam G Elshaug et al.   MEDICAL JOURNAL OF AUSTRALIA

2011 FDA drug approvals

(2012) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Mechanism of coordinated access to orphan drugs

(2012) R DeRidder et al.   Orphanet Journal of Rare Diseases

A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard

(2012) Christine Schmucker et al.   PLoS One

New Cystic Fibrosis Drug Offers Hope, at a Price

(2012) J. Kaiser   SCIENCE

Pharmaceutical research and development: what do we get for all that money?

(2012) D. W. Light et al.   BMJ-British Medical Journal

Access to orphan drugs in Europe: current and future issues

(2012) Morgane Michel et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

(2012) Marion Bennie et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Improving the managed entry of new medicines: sharing experiences across Europe

(2012) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

A Prescription for Improving Drug Formulary Decision Making

(2012) Gordon D. Schiff et al.   PLOS MEDICINE

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

(2012) Menno van Woerkom et al.   Journal of Comparative Effectiveness Research

Cost-Effectiveness Assessment of Orphan Drugs

(2012) Steven Simoens et al.   Applied Health Economics and Health Policy

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

(2011) Lars L. Gustafsson et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Time to revisit the orphan drug law

(2011) Silvio Garattini   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998–2010

(2011) Sylvain Pichetti et al.   HEALTH POLICY

A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland

(2011) Katarzyna Kolasa et al.   HEALTH POLICY

Scanning the horizon—Development and implementation of an early awareness system for anticancer drugs in Austria

(2011) Anna Nachtnebel et al.   HEALTH POLICY

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

(2011) Suerie Moon et al.   Globalization and Health

Access to orphan drugs despite poor quality of clinical evidence

(2010) Alain G. Dupont et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence

(2010) Laura Faden et al.   HEALTH POLICY

Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review

(2010) Geoffrey K. Spurling et al.   PLOS MEDICINE

Cyclosporine Versus Tacrolimus in Immunosuppressive Maintenance Regimens in Renal Transplants in Brazil: Survival Analysis from 2000 to 2004

(2009) Augusto Afonso Guerra et al.   ANNALS OF PHARMACOTHERAPY

Orphan drug development is not taking off

(2009) Roberta Joppi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The Italian Horizon Scanning Project

(2009) Roberta Joppi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Disinvestment for re-allocation: A process to identify priorities in healthcare

(2009) Sabina Nuti et al.   HEALTH POLICY

Potential savings without compromising the quality of care

(2009) C. Norman et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Information service on new and emerging health technologies: Identification and prioritization processes for a European Union–wide newsletter

(2009) Claudia Wild et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing

(2009) Bruce E. Hillner et al.   JOURNAL OF CLINICAL ONCOLOGY

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Recent National and Regional Drug Reforms in Sweden

(2009) Björn Wettermark et al.   PHARMACOECONOMICS

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

(2009) Anna Coma et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

(2009) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

A incorporação de novas tecnologias nos serviços de saúde: o desafio da análise dos fatores em jogo

(2008) Evelinda Trindade   Cadernos de Saude Publica

Enhancing the rational use of new medicines across European health care systems

(2008) Silvio Garattini et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Introducing Evidence-Based Medicine in Reimbursement Procedures: Does It Affect the Outcome?

(2008) Philippe Van Wilder et al.   VALUE IN HEALTH

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

(2008) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research